Clinical Trial Update: Phase II, 2nd Line Melanoma - RAND Monotherapy [Phase 2]

View source ↗

Summary

Phase II trial evaluating RAND Monotherapy for second-line melanoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Melanoma | Phase 2 | Status: COMPLETED